千葉大学大学院医学研究院細胞分子医学

論文・総説

2017年

  • #Tanaka T, #Nakajima-Takagi Y, #Aoyama K, Tara S, Oshima M, Saraya A, Koide S, Si S, Manabe I, Sanada M, Nakayama M, Masuko M, Sone H, Koseki H and *Iwama A. Internal deletion of BCOR reveals a tumor suppressor function for BCOR in T lymphocyte malignancies. J Exp Med 2017/08/22 online. (# 1st authors)
  • #Rizq O, #Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T, Ma A, Jin J, Iseki T, Nakaseko C, *Iwama A. Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent cancers to proteasome inhibition. Clin Cancer Res 23(16):4817-4830, 2017. (# 1st authors)
  • Okabe A, Funata S, Matsusaka K, Namba H, Fukuyo M, Rahmutulla B, Oshima M, Iwama A, Fukayama M, *Kaneda A. Regulation of tumour related genes by dynamic epigenetic alteration at enhancer regions in gastric epithelial cells infected by Epstein-Barr virus. Sci Rep 7(1):7924, 2017.
  • Oishi Y, Hayashi S, Isagawa T, Oshima M, Iwama A, Shimba S, Okamura H, *Manabe I. Bmal1 regulates inflammatory responses in macrophages by modulating enhancer RNA transcription. Sci Rep 7(1):7086, 2017.
  • Kaneta, Y, Arai M, Ishikawa N, Toume, K, Koyano T, Kowithayakorn T, Chiba T, Iwama A, and *Ishibashi M. Identification of BMI1 Promoter Inhibitors from Beaumontia murtonii and Eugenia operculata. J Nat Prod 80(6):1853-1859, 2017.
  • Ueda K, *Ikeda K, Ikezoe T, Harada-Shirado K, Ogawa K, Hashimoto Y, Sano T, Ohkawara H, Kimura S, Shichishima-Nakamura A, Nakamura Y, Shikama Y, Mori T, Mason PJ, Bessler M, Morishita S, Komatsu N, Shide K, Shimoda K, Koide S, Aoyama K, Oshima M, Iwama A, and Takeishi Y. HMGA2 collaborates with JAK2V617F in the development of myeloproliferative neoplasms. Blood Advances, 1(15):1001-1015, 2017.
  • Seki M, Kimura S, Isobe T, Yoshida K, Ueno H, Nakajima-Takagi Y, Wang C, Lin L, Kon A, Suzuki H, Shiozawa Y, Kataoka K, Fujii Y, Shiraishi Y, Chiba K, Tanaka H, Shimamura T, Masuda K, Kawamoto H, Ohki K, Kato M, Arakawa Y, Koh K, Hanada R, Moritake H, Akiyama M, Kobayashi R, Deguchi T, Hashii Y, Imamura T, Sato A, Kiyokawa N, Oka A, Hayashi Y, Takagi M, Manabe A, Ohara A, Horibe K, Sanada M, Iwama A, Mano H, Miyano S, *Ogawa S, *Takita J. Recurrent PU.1 (SPI1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet 49(8):1274-1281, 2017.
  • *Iwama A. Polycomb repressive complexes in hematological malignancies. (Review) Blood 130(1): 23-29, 2017.
  • Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, *Nakaseko C, Naoe T. Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia. Blood Cancer J 7(4):e559, 2017.
  • Kinoshita D, Nagasawa A, Shimizu I, Ito TK, Yoshida Y, Tsuchida M, Iwama A, Hayano T, *Minamino T. Progerin impairs vascular smooth muscle cell growth via the DNA damage response pathway. Oncotarget 8(21):34045-34056, 2017.
  • Mito K, Sato Y, Kobayashi T, Miyamoto K, Nitta E, Iwama A, Matsumoto M, Nakamura M, Sato K, *Miyamoto T. The nicotinic acetylcholine receptor α7 subunit is an essential negative regulator of bone mass. Sci Rep 2017 Mar 28;7:45597.
  • Nishida Y, Maeda A, Kim MJ, Cao L, Kubota Y, Ishizawa J, Rawi AN, Kato Y, Iwama A, Fujisawa M, Matsue K, Weetall M, Dumble M, Andreeff M, Davis TW, Branstrom A, Kimura S *Kojima K. The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells. Blood Cancer J 7(2):e527, 2017.
  • Yokoyama M, *Chiba T, Zen Y, Oshima M, Kusakabe Y, Noguchi Y, Yuki K, Koide S, Tara S, Saraya A, Aoyama K, Mimura N, Miyagi S, Inoue M, Wakamatsu T, Saito T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Otsuka M, Miyazaki M, Yokosuka O, Iwama A. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma. Oncotarget 8(13):21315-21326, 2017.
  • Loo TM, Kamachi F, Watanabe Y, Yoshimoto S, Kanda H, Arai Y, Nakajima-Takagi Y, Iwama A, Koga T, Sugimoto Y, Ozawa T, Nakamura M, Kumagai M, Watashi K, Taketo MM, Aoki T, Narumiya S, Oshima M, Arita M, Hara E and *Ohtani N. Gut microbiota promotes obesity-associated liver cancer through PGE2-mediated suppression of antitumor immunity. Cancer Discovery 7(5):522-538, 2017.
  • #Hasegawa N, #Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K,Kaneda A, Shimoda K, Nakaseko C, Yokote K, *Iwama A. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia 31(4):861-871, 2017. (# 1st authors)
  • Sashida G, *Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. (Review) Int J Hematol 105(1):23-30, 2017

2016年

  • Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, Neuberg D, Tenen DG, Levantini E. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinomas with low CEBPα expression. Sci Transl Med 8(350):350ra104, 2016.
  • Shimizu R, Muto T, Aoyama K, Choi K, Takeuchi M, Koide S, Hasegawa N, Isshiki Y, Togasaki E, Kawajiri C, Nagao Y, Tsukamoto S, Sakai S, Takeda Y, Mimura N, Ohwada C, Sakaida E, Iseki T, Starczynowski D-T, Iwama A, Yokote K, Nakaseko C. Possible role of intragenic hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia. Leuk Lymphoma 50:85-94, 2016.
  • Sashida G, Wang S, Tomioka T, Oshima M, Kazumasa Aoyama K, Kanai A, Mochizuki-Kashio M, Harada H, Shimoda K, *Iwama A. The loss of Ezh2 cooperates with an active JAK2 mutant in the pathogenesis of myelofibrosis and sensitizes tumor-initiating cells to bromodomain inhibition. J Exp Med 213(8):1459-1477, 2016.
  • Koide S, Oshima M, Takubo K, Yamazaki S, Nitta E, Saraya A, Aoyama K, Kato Y, Miyagi S, Nakajima-Takagi Y, Chiba T, Matsui H, Arai F, Suzuki Y, Kimura H, Nakauchi H, Suda T, Shinkai Y, and *Iwama A. Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of non-hematopoietic genes. Blood 128(5):638-649, 2016.
  • Kuribayashi W, Takizawa K, Sugata K, Kuramitsu M, Momose H, Sasaki E, Hiradate Y, Furuhata K, Asada Y, Iwama A, Matsuoka M, Mizukami T, Hamaguchi I. Impact of the SCF signaling pathway on leukemia stem cell-mediated ATL initiation and progression in an HBZ transgenic mouse model. Oncotarget 2016;7(32):51027-51043.
  • Kanda M, Nagai T, Takahashi T, Liu M-L, Kondou N, Naito AT, Akazawa H, Sashida G, Iwama A, Komuro I, Kobayashi Y. Leukemia inhibitory factor enhances endogenous cardiomyocyte regeneration after myocardial infarction. Plos One 11(5):e0156562.
  • #Si S, #Nakajima-Takagi Y, Aoyama K, Oshima M, Saraya A, Sugishita H, Nakayama M, Ishikura T, Koseki H, *Iwama A. Loss of Pcgf5 affects global H2A monoubiquitination but not the function of hematopoietic stem and progenitor cells. Plos One 11(5):e0154561, 2016. (# 1st authors)
  • Oshima M, Hasegawa N, Mochizuki-Kashio M, Muto T, Miyagi S, Koide S, Yabata S, Wendt G, Saraya A, Wang C, Shimoda K, Suzuki Y, *Iwama A. Ezh2 regulates the Lin28/let-7 pathway to restrict activation of fetal gene signature in adult hematopoietic stem cells. Exp Hematol 44:282-296, 2016.
  • Sekine A, Nishiwaki T, Nishimura R, Kawasaki T, Urishibara T, Suda R, Suzuki T, Takayanagi S, Terada J, Sakao S, Tada Y, Iwama A, Tatsumi K. Prominin-1/CD133 expression as potential tissue-resident vascular endothelial progenitor cells in the pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 310(11):L1130-42, 2016.
  • Kurimoto R, Iwasawa S, Ebata T, Ishiwata T, Sekine I, Tada Y, Tatsumi K, Koide S, Iwama A, Takiguchi Y. Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation. Int J Oncol 48(5):1825-36, 2016.
  • Seed TM, Xiao S, Manley N, Nikolich-Zugich J, Pugh J, Van den Brink M, Hirabayashi Y, Yasutomo K, Iwama A, Koyasu S, Shterev I, Sempowski G, Macchiarini F, Nakachi K, Kunugi KC, Hammer CG, Dewerd LA. An interlaboratory comparison of dosimetry for a multi-institutional radiobiological research project: Observations, problems, solutions and lessons learned. Int J Radiat Biol 92(2):59-70, 2016.
  • Chiba T, Iwama A, and Yokosuka O. Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. Hepatology Research 46(1):50-57, 2016.

2015年

  • Oshima M and Iwama A. Nuclear, not cytoplasmic PKR maneuvers in AML. (Inside Blood) Blood 126:1523-1524, 2015.
  • Kamiya A, Ito K, Yanagida A, Iwama A, and Nakauchi H. MEK-ERK activity regulates the proliferative activity of fetal hepatoblasts through accumulation of p16/19cdkn2a. Stem Cells and Development 24:2525-2535, 2015.
  • Mochizuki-Kashio M, Aoyama K, Sashida G, Oshima M, Tomioka T, Muto T, Wang C, and Iwama A. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner. Blood 126:1172-1183, 2015
  • Wang C, Oshima M, Gashida G, Tomioka T, Hasegawa N, Mochizuki-Kashio M, Nakajima-Takagi Y, Kusunoki Y, Kyoizumi S, Imai K, Nakachi K, and Iwama A. Non-lethal ionizing radiation promotes aging-like phenotypic changes of human hematopoietic stem and progenitor cells in humanized mice. Plos One 2015;10(7):e0132041.
  • Chiba T, Iwama A, and Yokosuka O. Cancer stem cells in hepatocellular carcinoma: Therapeutic implications based on stem cell biology. Hepatology Research 46(1):50-57, 2016.
  • Ueda T, Nagamachi A, Takubo K, Yamasaki N, Matsui H, Kanai A, Nakata Y, Ikeda K, Konuma T, Oda H, Wolff L, Honda Z-I, Wu X, Helin K, Iwama A, Suda T, Inaba T, and Honda H. Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2. Blood 2015;125(22):3437-46.
  • Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Sashida G, Aoyama K, Yoshimitsu M, Abe H, Miike T, Iwakiri H, Tahara Y, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasm. Genom Data 4:102-108, 2015.
  • Matsushita M, Kitamura K, Rahmutulla B, Tanaka N, Ishige T, Satoh M, Hoshino T, Miyagi S, Mori T, Itoga S, Shimada H, Tomonaga T, Kito M, Nakajima-Takagi Y, Kubo S, Nakaseko C, Hatano M, Miki T, Matsuo M, Kaneda A, Iwama A and Nomura F. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. Oncotarget 6:5102-5017, 2015
  • Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Ohtsuka M, Miyazaki M, Iwama A, and Yokosuka O. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 136:289-298, 2015.
  • Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Loss-of-TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 125:304-315, 2015.
  • 岩間厚志 (2015) 「造血幹細胞のエピジェネティクス」Annual Review 呼吸器 2015(永井厚志、巽浩一郎、桑野和善、高橋和久編) pp.15-23, 中外医学社、東京
  • 指田吾郎、岩間厚志 (2015)「骨髄異形成症候群におけるエピジェネティック異常」臨床血液 56(2):111-117.
  • 武藤朋也、岩間厚志 (2015)「ポリコーム群遺伝子と骨髄異形成」医学のあゆみ252(9): 964-966.
  • 仁田英里子、岩間厚志 (2015)「がん幹細胞化のメカニズム」日本臨床 73(5): 733-738.

2014年

  • Kameda T, Shide K, Yamaji T, Kamiunten A, Sekine M, Taniguchi Y, Hidaka T, Kubuki Y, Shimoda H, Marutsuka K, Sashida G, Aoyama K, Yoshimitsu M, Harada T, Abe H, Miike T, Iwakiri H, Tahara Y, Sueta M, Yamamoto S, Hasuike S, Nagata K, Iwama A, Kitanaka A, Shimoda K. Loss-of-TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator. Blood 2014 Nov 13. pii: blood-2014-04-555508. [Epub ahead of print]
  • Mishima Y, Wang C, Miyagi S, Saraya A, Hosokawa H, Mochizuki-Kashio M, Nakajima-Takagi Y, Koide S, Negishi M, Sashida G, Naito T, Ishikura T, Onodera A, Nakayama T, Tenen DG, Yamaguchi N, Koseki H, Taniuchi I, and Iwama A. Histone acetylation mediated by Brd1/Brpf2 is crucial for Cd8 gene activation during early thymocyte development. Nat Commun 5:5872, 2014.
  • Oshima M, Iwama A. Epigenetics of hematopoietic stem cell aging and disease. Int J Hematol 100:326-334, 2014.
  • Nitta E and Iwama A. Diploid not polyploid: new platelet producers. (Inside Blood) Blood 124:2620-2622, 2014.
  • Mimura N, Hideshima T, Suzuki R, Ohguchi H, Cottini F, Tai U-T, Cirstea D, Gorgun G, Minami J, Shimomura T, Utsugi T, Richardson PG, Iwama A, and Anderson KC. Preclinical activity of a novel selective Akt inhibitor TAS-117 in multiple myeloma. Cancer Res 74:4458-4469, 2014.
  • Anani M, Nobuhisa I, Osawa M, Iwama A, Harada K, Saito K, and Taga T. Sox17 as a candidate regulator of myeloid restricted differentiation potential. Dev Growth Differ 56:469-479, 2014.
  • Sashida G, Harada H, Matsui H, Oshima M, Yui M, Harada Y, Tanaka S, Mochizuki-Kashio M, Wang C, Saraya A, Muto T, Inaba T, Koseki H, Huang G, Kitamura T, and Iwama A. Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukemic transformation. Nat Commun 5:4177, 2014.
  • Chiba T, Saito T, Yuki K, Zen Y, Koide S, Kanogawa N, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Ohtsuka M, Miyazaki M, Iwama A, and Yokosuka O. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma. Int J Cancer 2014 May 21. doi: 10.1002/ijc.28985. [Epub ahead of print].
  • Hayashi Y, Kuroda T, Kishimoto H, Wang C, Iwama A, Kimura K. Downregulation of rRNA transcription triggers cell differentiation. PLoS One 9:e98586, 2014.
  • Muto T, Sashida G, Hasegawa N, Nakaseko C, Yokote K, Shimoda K and Iwama A. MDS with extramedullary erythroid hyperplasia induced by loss of Tet2 in mice. Leuk Lymphoma 17:1-4, 2014.
  • Wang C, Sashida G, Saraya A, Ishiga R, Koide S, Oshima M, Ishono K, Koseki H, and Iwama A. Depletion of Sf3b1 impairs proliferative capacity of hematopoietic stem cells but is not sufficient to induce myelodysplasia. Blood 123:3336-3343, 2014.
  • Fukumoto Y, Morii M, Miura T, Kubota S, Ishibashi K, Honda T, Okamoto A, Yamaguchi N, Iwama A, Nakayama Y and Yamaguchi N. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint. J Biol Chem 289:12313-12329, 2014.
  • Yamaguchi Y, Takenobu H, Ohira M, Nakazawa A, Yoshida S, Akita N, Shimozato O, Iwama A, Nakagawara A, Kamijo T. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway. Eur J Cancer. 50:1555-1565, 2014.
  • Nobuhisa I, Osawa M, Uemura M, Kishikawa Y, Anani M, Harada K, Takagi H, Saito K, Kanai-Azuma M, Kanai Y, Iwama A and Taga T. Sox17-mediated maintenance of fetal intra-aortic hematopoietic cell clusters. Mol Cell Biol 34:1976-1990, 2014.
  • Miyagi S, Koide S, Saraya A, Wendt GR, Oshima M, Konuma T, Yamazaki S, Mochizuki-Kashio M, Nakajima-Takagi Y, Wang C, Chiba T, Kitabayashi I, Nakauchi H and Iwama A. The Tif1β-Hp1 system maintains transcriptional integrity of hematopoietic stem cells. Stem Cell Reports 2:145-152, 2014.
  • Chiba T, Suzuki E, Yuki K, Zen Y, Oshima M, Miyagi S, Saraya A, Koide S, Motoyama T, Ogasawara S, Ooka Y, Tawada A, Nakatsura T, Hayashi T, Yamashita T, Kaneko S, Miyazaki M, Iwama A, Yokosuka O. Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners. PLoS One 9:e84807, 2014.
  • Nakajima-Takagi Y, Osawa M, and Iwama A. Manipulation of hematopoietic stem cells for regenerative medicine. (Review) Anat Rec 297:111-120, 2014.
  • 指田吾郎、岩間厚志(2014)「癌細胞におけるエピゲノム制御異常」医学のあゆみ 250:52-58.
  • 長谷川渚、指田吾郎、岩間厚志 (2014) 「造血器悪性疾患におけるエピゲノム異常」血液フロンティア24:1755-1762.

2013年

  • Muto T*, Sashida G*, Oshima M*, Wendt GR, Mochizuki-Kashio M, Nagata Y, Sanada M, Miyagi S, Saraya A, Kamio A, Nagae G, Nakaseko C, Yokote K, Shimoda K, Koseki H, Suzuki Y, Sugano S, Aburatani H, Ogawa S, and Iwama A. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210:2627-2639, 2013. (*equally contributed)
  • Iwama A. Recent advances in stem cell biology in regeneration and disease. (Editorial) Inflammation and Regeneration 33:173-174, 2013.
  • Koide S, Wendt G, and Iwama A. Epigenetic regulation of hematopoietic stem cells. (Mini-review) Inflammation and Regeneration 33:199-202, 2013.
  • Kitazono S, Takiguchi Y, Ashinuma H, Saito-Kitazono M, Kimura A, Chiba T, Sakaida E, Sekine I, Tada Y, Kurosu K, Sakao S, Tanabe N, Iwama A, Yokosuka O and Tatsumi K. Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line. Int J Oncol 43:1846-1854, 2013.
  • Saito T, Chiba T, Yuki K, Zen Y, Oshima M, Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, Tawada A, Tada M, Kanai F, Takiguchi Y, Iwama A, Yokosuka O. Metformin, a diabetes drug, eliminates tumor-initiating hepatocellular carcinoma cells. Plos One, 8(7), e70010, 2013.
  • Chiba T, Kanai F, Iwama A, Yokosuka O. Circulating cancer stem cells: a novel prognostic predictor of hepatocellular carcinoma. HepatoBiliary Surg Nutr 2, 4-6, 2013
  • Harada Y, Inoue D, Ding Y, Imagawa J, Doki N, Matsui H, Yahata T, Matsushita H, Ando K, Sashida G, Iwama A, Kitamura T, and Harada H. RUNX1/AML1 mutant collaborates with BMI1 overexpression in the development of human and murine myelodysplastic syndromes. Blood 121, 3434-3446, 2013.
  • *Nakajima-Takagi Y, *Osawa M, Oshima M, Takagi H, Miyagi S, Endoh M, Endo TA, Takayama N, Eto K, Toyoda T, Koseki H, Nakauchi H, and Iwama A. Role of SOX17 in hematopoietic development from human embryonic stem cells. Blood 121, 447-458, 2013. (*equally contributed)
  • Wang C, Nakamura S, Oshima M, Mochizuki-Kashio M, Nakajima-Takagi Y, Osawa M, Kusunoki Y, Kyoizumi S, Imai K, Nakachi K, and Iwama A. Compromised hematopoiesis and increased DNA damage following non-lethal ionizing radiation of a human hematopoietic system reconstituted in immunodeficient mice. Int J Rad Biol 89, 132-137, 2013.
  • Wendt G, Nakamura S, and Iwama A. Crucial role of the polycomb group gene product BMI-1 in the maintenance of self-renewing hematopoietic stem cells. In Therapeutic Applications in Disease and Injury (Hayat MA eds) Stem Cells and Cancer Stem Cells Volume 9, 2013, pp 143-153, Springer.
  • 中島やえ子、岩間厚志 (2013)「ポリコーム群複合体の機能低下と造血幹細胞老化」内分泌・糖尿病・代謝内科 37(2):212-216.
  • 岩間厚志 (2013) 「造血幹細胞のエピジェネティクス」Annual Review 血液(高久史麿、小澤敬也、坂田洋一、金倉譲、小島勢二編) pp.1-8, 中外医学社、東京
  • 岩間厚志 (2013)「幹細胞老化とエピジェネティクス」アンチ・エイジング医学-日本抗加齢医学会雑誌 9(1):16-22. pp.1-8.
  • 岩間厚志 (2011)「造血器腫瘍における癌抑制遺伝子としてのポリコーム群遺伝子の機能」臨床血液 54(7):642-648.

2012年

  • Iwama A. Epigenetics of hematopoiesis and hematological malignancies. (Editorial) Int J Hematol 96:403-404, 2012.
  • Sashida G and Iwama A. Epigenetic regulation of hematopoiesis. Int J Hematol 96:405-412, 2012.
  • Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K, Koseki H, and Iwama A. Ezh2 augments leukemogenecity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120, 1107-1117, 2012.
  • Zhang Y*, Yan X*, Sashida G*, Zhao X, Rao Y, Goyama S, Whitman SP, Zorko N, Bernot K, Conway RM, Witte D, Wang Q, Tenen DG, Xiao Z, Marcucci Z, Mulloy JC, Grimes HL, Caligiuri MA, and Huang G. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood 120, 1118-1129, 2012. (*equally contributed)
  • Sakai S, Nakaseko C, Takeuchi M, Ohwada C, Shimizu N, Tsukamoto S, Kawaguchi T, Jiang M, Sato Y, Ebinuma H, Yokote K, Iwama A, Fukamachi I, Schneider WJ, Saito Y, and Bujo H. Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clinica Chemica Acta 413, 1542-1548, 2012.
  • Shide K, Kameda T, Shimoda H, Yamaji T, Abe H, Kamiunten A, Sekine M, Hidaka T, Katayose K, Kubuki Y, Yamamoto S, Miike T, Iwakiri H, Hasuike S, Nagata K, Iwama A, Matsuda T, Kitanaka A and Shimoda K. TET2 is essential for survival and hematopoietic stem cell homeostasis. Leukemia 26, 2216-2223, 2012.
  • Suzuki E, Chiba T, Zen Y, Miyagi S, Tada M, Kanai F, Imazeki F, Miyazaki M, Iwama A, and Yokosuka O. Aldehyde dehydrogenase 1 is associated with recurrence-free survival but not stem cell-like properties in hepatocellular carcinoma. Hepatol Res 42, 1100-1111, 2012.
  • Mochizuki-Kashio M, Went G, and Iwama A. Tumor suppressor function of the polycomb group genes. (Editorials) Cell Cycle 11, 2043-2044, 2012.
  • Nakamura S, Oshima M, Yuan J, Saraya A, Miyagi S, Konuma T, Yamazaki S, Osawa M, Nakauchi H, Koseki H, and Iwama A. Bmi1 confers resistance to oxidative stress on hematopoietic stem cells. PLoS ONE 7, e36209, 2012.
  • Ashinuma H, Takiguchi Y, Kitazono S, Kitazono-Saitoh M, Kitamura A, Chiba T, Tada Y, Kurosu K, Sakaida E, Sekine I, Tanabe N, Iwama A, Yokosuka O, Tatsumi K. Anti-proliferative action of metformin in human lung cancer cell lines. Oncology Reports 28, 8-14, 2012.
  • Nishino T, Osawa M, and Iwama A. New approaches to expand hematopoietic stem and progenitor cells. (Review) Expert Opin Biol Ther 12, 743-756, 2012.
  • Oguro H*, Yuan J*, Tanaka S, Miyagi S, Mochizuki-Kashio M, Ichikawa H, Yamazaki S, Koseki H, Nakauchi H, and Iwama A. Lethal myelofibrosis induced by Bmi1-deficient hematopoietic cells unveils a tumor suppressor function of the polycomb group genes. J Exp Med 209, 445-454, 2012. (*equally contributed)
  • 岩間厚志 (2012) 「幹細胞のエピジェネティクス」「再生医療叢書1幹細胞」(山中伸弥、中内啓光編) pp.142-156, 朝倉書店、東京
  • 指田吾郎、千葉哲博、岩間厚志 (2012)「癌幹細胞とエピゲノム制御異常」細胞工学 31:24-31.
  • 指田吾郎、岩間厚志 (2012)「白血病幹細胞におけるエピジェネティクス制御」「造血器腫瘍とエピジェネティクス」 pp.60-70, 医薬ジャーナル、大阪
  • 岩間厚志 (2012) 「造血幹細胞」「みんなに役立つ造血幹細胞移植の基礎と臨床」(神田善伸編) pp. 28-34,医薬ジャーナル社,大阪

2011年

  • Mochizuki-Kashio M, Mishima Y, Miyagi S, Negishi M, Saraya A, Konuma T, Shinga J, Koseki H, and Iwama A. Dependency on the polycomb protein Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood 118, 6553-6561, 2011.
  • Yamazaki S, Ema H, Karlsson G, Yamaguchi T, Miyoshi H, Shioda S, Taketo MM, Karlsson S, Iwama A, and Nakauchi H. Non-myelinating Schwann cells in the mouse bone marrow niche maintain haematopoietic stem cell hibernation through TGF-β signaling. Cell 147, 1146-1158, 2011.
  • Nishino T, Wang C, Mochizuki-Kashio, M, Osawa, M, Nakauchi, H, and Iwama A. Ex vivo expansion of human hematopoietic stem cells by Garcinol, a potent inhibitor of histone acetyltransferase. PLoS ONE 6: e24298, 2011
  • Mishima Y*, Miyagi S*, Saraya A*, Negishi M, Endoh M, Endo TA, Toyoda T, Shinga J, Katsumoto T, Chiba T, Yamaguchi N, Kitabayashi I, Koseki H, and Iwama A. The Hbo1-Brd1/Brpf2 complex is responsible for global acetylation of H3K14 and required for fetal liver erythropoiesis. Blood 118, 2443-2453, 2011. (*equally contributed)
  • Yuan J, Takeuchi M, Negishi M, Oguro H, Ichikawa H, and Iwama A. Bmi1 is essential for leukemic reprogramming of myeloid progenitor cells. Leukemia 25, 1335-1343.2011
  • Chiba T*, Suzuki E*, Negishi M, Saraya A, Miyagi S, Konuma T, Tanaka S, Tada M, Kanai F, Imazeki F, Iwama A, and Yokosuka O. 3-deazaneplanocin is a promising therapeutic agent for the eradication of tumor-initiating hepatocellular carcinoma cells. Int J Cancer 2011 Jun 29. doi: 10.1002/ijc.26264. [Epub ahead of print]. (*equally contributed)
  • Konuma T, Nakamura S, Miyagi S, Negishi M, Chiba T, Oguro H, Yuan J, Mochizuki-Kashio M, Ichikawa H, Miyoshi H, Vidal M and Iwama A. Forced expression of the histone demethylase Fbxl10 maintains self-renewing hematopoietic stem cells. Exp Hematol 39, 697-709, 2011.
  • Oshima M, Endoh M, Endo TA, Toyoda T, Nakajima-Takagi Y, Sugiyama F, Koseki H, Iwama A, and Osawa M. Genome-wide analysis of target genes regulated by HoxB4 in hematopoietic stem and progenitor cells developing from embryonic stem cells. Blood 117, e142-150, 2011.
  • Takeda Y, Nakaseko C, Tanaka H, Takeuchi M, Yui M, Saraya A, Miyagi S, Wang C, Tanaka S, Ohwada C, Sakaida E, Yamaguchi N, Yokote K, Hennighausen L, and Iwama A. Direct activation of STAT5 by ETV6-Lyn fusion protein promotes induction of myeloproliferative neoplasm with myelofibrosis. Br J Haematol 153, 589-598, 2011.
  • Guo Y, Miyazaki M, Itoi M, Satoh R, Iwama A, Amagai T, Kawamoto H, Kanno M. Polycomb group gene Bmi1 plays a role in the growth of thymic epithelial cells. Eur J Immunol 41, 1098-1107, 2011.
  • 指田吾郎、岩間厚志 (2011)「造血」疾患モデルマウス表現型解析指南 (山村研一、若菜茂晴編集) pp.248-253,中山書店,東京.
  • 小沼貴晶、岩間厚志 (2011) 「白血病幹細胞の維持機構」実験医学増刊号 Vol29 No20「がん幹細胞」(須田年生編集),pp. 87-95. 羊土社,東京.
  • 岩間厚志 (2011) 「エピジェネティクスと癌」Medchem News 21(4):18-23.
  • 岩間厚志 (2011)「造血器腫瘍のエピゲノム」臨床血液 52(10):275-283.
  • 岩間厚志 (2011) 「造血幹細胞のヒストンメチル化修飾による制御機構」血液内科 63:242-247.
  • 宮城聡、三嶋雄太、岩間厚志 (2011)「MYSTファミリーに属するヒストンアセチル化酵素の構造と機能」臨床血液 52(7):490-496.
  • 千葉哲博、岩間厚志 (2011)「癌幹細胞の発生・維持機構」 Frontiers in Gastroenterology 16, 240-245, 2011.
  • 岩間厚志 (2011)「幹細胞研究は何を明らかにしつつあるのか」実験医学 29:2-8.
  • 宮城聡、小黒秀行、岩間厚志 (2011)「幹細胞の多能性を規定するエピジェネティック機構」実験医学 29:21-28.
  • 岩間厚志 (2011) 「造血幹細胞のエピジェネティクス」 中国科学技術月報 1月号(第51号)

2010年

  • Negishi M, Saraya A, Mochizuki S, Helin K, Koseki H, and Iwama A. A novel zinc finger protein Zfp277 mediates transcriptional repression of the Ink4a/Arf locus through polycomb repressive complex 1. PLoS ONE 5(8).pii: e12373,2010.
  • Konuma T, Oguro H, and Iwama A. Role of polycomb group proteins in hematopoietic stem cells. Dev Growth Differ 52, 505-516, 2010.
  • Chiba T, Seki A, Aoki R, Ichikawa H, Negishi M, Miyagi S, Oguro H, Saraya A, Kamiya A, Nakauchi H, Yokosuka O, and Iwama A. The polycomb-group gene Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and independent manners. Hepatology 52,1111-1123,2010.
  • Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL, Ueno T, Soda M, Hamada T, Haruta H, Takada S, Miyazaki Y, Kiyoi H, Ito E, Naoe T, Tomonaga M, Toyota M, Tajima S, Iwama A, and Mano H. Array-based genomic resequencing of human leukemia. Oncogene 24, 3723-3731, 2010.
  • Sugawara T, Oguro H, Negishi M, Morita Y, Ichikawa H, Iseki T, Yokosuka O, Nakauchi H, Iwama A. FET family proto-oncogene Fus contributes to self-renewal of hematopoietic stem cells. Exp Hematol. 38, 696-706, 2010.
  • Koizumi T, Negishi M, Nakamura S, Oguro H, Satoh K, Ichinose M, and Iwama A. Depletion of Dnmt1-associated protein 1 triggers DNA damage and compromises the proliferative capacity of hematopoietic stem cells. Int J Hematol 91, 611, 2010.
  • Aoki R, Chiba T, Miyagi S, Negishi M, Konuma T, Taniguchi H, Ogawa M, Yokosuka O, and Iwama A. The polycomb-group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells. J Hepatology 52, 854-863, 2010.
  • Oguro H, Yuan J, Ichikawa H, Ikawa T, Yamazaki S, Kawamoto H, Nakauchi H, and Iwama A. Poised lineage specification in multipotent hematopoietic stem and progenitor cells by the polycomb protein Bmi1. Cell Stem Cell 6, 279-286, 2010.
  • Tanaka H, Takeuchi M, Takeda Y, Sakai S, Oda K, Abe D, Ohwada C, Ozawa S, Sakaida E, Shimizu N, Saito Y, Miyagi S, Iwama A, and Nakaseko C. Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis. Leukemia 24, 197-200, 2010.
  • 岩間厚志(2010)「エピジェネティクスと再生医療」CARDIAC PRACTICE 21:385-390.
  • 岩間厚志 (2010)「癌におけるポリコーム群複合体の機能と新規標的分子としての可能性」臨床血液 51(8):605-611.
  • 岩間厚志 (2010) 「がん幹細胞を標的とした治療法の動向」細胞 42:310-311.
  • 千葉哲博、小沼貴晶、岩間厚志 (2010) 「がん幹細胞をエピジェネティック治療の可能性」細胞 42:330-333.
  • 小沼貴晶、千葉哲博、岩間厚志 (2010) 「癌のエピジェネティクス異常」再生医療 9:222-228.
  • 袁進、岩間厚志 (2010) 「白血病幹細胞研究の進歩」血液腫瘍科 60:113-117.
  • 小沼貴晶、岩間厚志 (2010) 「白血病幹細胞の自己複製機構」血液フロンティア 20:421-430.
  • 大澤光次郎、大津真、岩間厚志 (2010) 「造血幹細胞と再生医療」実験医学1月増刊号 Vol28 No2「再生医療の最前線2010〜ES・iPS・組織幹細胞の特性の理解と分化誘導、創薬・臨床応用に向けた品質管理、安全性の基盤技術」(中辻憲夫、中内啓光監修),pp. 113-120. 羊土社,東京.

2009年

  • Nishino T, Miyaji K, Ishiwata N, Arai K, Yui M, Asai Y, Nakauchi H, and Iwama A. Ex vivo expansion of human hematopoietic stem cells by a small-molecule agonist of c-MPL. Exp Hematol 37, 1364-1377, 2009.
  • Negishi M, Chiba T, Saraya A, Miyagi S, and Iwama A. DMAP1 is essential for the recruitment of Pcna to repair foci. Genes Cells 14, 1347-1357, 2009.
  • Komatsu S, Takenobu H, Ozaki T, Ando K, Koida N, Suenaga Y, Ichikawa T, Hishiki T, Chiba T, Iwama A, Yoshida H, Ohnuma N, Nakagawara A and Kamijo T. Plk1 regulates liver tumor cell death by phosphorylation of TAp63. Oncogene 28, 3631-3641, 2009.
  • Xiao W, Hong H, Kawakami Y, Kato Y, Wu D, Yasudo H, Kimura A, Kuwabara H, Bertoli LF, Davis RS, Chau LA, Madrenas J, Hsia CC, Xenocostas A, Kipps TJ, Hennighausen L, Iwama A, Nakauchi H, and Kawakami T. Tumor suppression by phospholipase C-β3 via SHP-1-mediated dephosphorylation of Stat5. Cancer Cell, 16, 161-171, 2009.
  • Chiba T, Kamiya A, Yokosuka O, and Iwama A. Cancer stem cells in hepatocellular carcinoma: recent progress and perspective. Cancer letters, 286, 145-153, 2009.
  • Yonemitsu Y, Imazeki F, Chiba T, Fukai K, Nagai Y, Miyagi S, Arai M, Aoki R, Miyazaki M, Nakatani Y, Iwama A, Yokosuka O. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma. Hum Pathology 40, 1304-1311, 2009.
  • Feng J, Iwama A, Satake M, and Kohu K. MicroRNA-27 enhances differentiation of myeloblasts into granulocytes by post-transcriptionally down-regulating Runx1. Br J Haematol 145, 412-23, 2009.
  • Fukushima K, Matsumura I, Ezoe S, Tokunaga M, Yasumi K, Satoh Y, Shibayama H, Tanaka H, Iwama A, and Kanakura Y. FIP1L1-PDGFRα imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells. J Biol Chem 284, 7719-7732, 2009.
  • Yamazaki S, Iwama A, Takayanagi SI, Eto K, Ema H, and Nakauchi H. TGF-β as a candidate bone marrow niche signal to induce hematopoietic stem cell hibernation. Blood 113, 1250-1256, 2009.
  • Yashiro Y, Bannai H, Yabiku T, Minowa T, Miyano S, Osawa M, Iwama A, Nakauchi H. Transcriptional profiling of hematopoietic stem cells by high-throughput sequencing. Int J Hematol 89, 24-33, 2009.
  • 岩間厚志 (2009) 「癌幹細胞の自己複製制御機構」医学のあゆみ増刊号 9月「癌幹細胞—癌研究のパラダイムシフト」(赤司浩一編集) pp. 51-56,医歯薬出版、東京
  • 岩間厚志 (2009)「幹細胞のエピジェネティクス」ゲノム医学 9:171-175.
  • 千葉哲博、岩間厚志 (2009)「エピジェネティクスからみた癌幹細胞の制御は可能か」Surgery Frontier 16:351-354.
  • 岩間厚志 (2009)「造血系癌幹細胞(白血病幹細胞)」「炎症・再生医学辞典」(松島綱治、西脇徹編) pp.430-432,朝倉書店,東京 (2009)
  • 岩間厚志 (2009) 「白血病幹細胞」「造血器腫瘍アトラス」(阿部達生編) pp.37-43,日本医事新報社,東京 (2009)
  • 宮城聡、岩間厚志 (2009) 「ポリコーム複合体による幹細胞制御」最新医学増刊号Vo64 3月「幹細胞研究の最新の進歩」(須田年生監修) pp. 148-158,最新医学社,東京.
  • 千葉哲博、岩間厚志(2009)「癌幹細胞の維持に働く遺伝子」Surgery Frontier 16:7-14.
  • 千葉哲博、岩間厚志 (2009) 「ポリコーム複合体による癌幹細胞の制御機構」実験医学増刊号Vol27 No2「癌と微小環境」(江角浩安、高倉伸幸、宮園浩平、森正樹編) pp. 29-35,羊土社,東京.

2008年

  • Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H, and Iwama A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 68, 7742-7749, 2008.
  • Miyagi S, Masui S, Niwa H, Saito T, Shimazaki T, Okano H, Nishimoto M, Muramatsu M, Iwama A, Okuda A. Consequence of the loss of Sox2 in the developing brain of the mouse. FEBS Lett. 582, 2811–2815, 2008.
  • Yamashita M, Kuwahara M, Suzuki A, Hirahara K, Shinnakatsu R, Hosokawa H, Hasegawa A, Motohashi S, Iwama A, and Nakayama T. Bmi1 regulates memory CD4 T cell survival via repression of the Noxa gene. J Exp Med 205, 1109-1120, 2008.
  • Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K, Nagamatsu G, Nakamura Y, Gomei Y, Iwasaki H, Shima H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A, Chiba S, Nakayama K-I, and Suda T. Fbxw7 acts as a critical failsafe against premature loss of hematopoietic stem cells and development of T-ALL. Genes & Dev 22, 986-991, 2008.
  • Mizukami T, Kuramitsu M, Takizawa K, Momose H, Masumi A, Naito S, Iwama A, Ogawa T, Nose T, Hamaguchi I, and Yamaguchi K. Identification of transcripts commonly expressed in hematopoietic and germline stem cells. Stem Cells and Development 17, 67-80, 2008.
  • Takeuchi M, Nakaseko C, Miyagi S, Takeda Y, Ozawa S, Ohwada C, Cho R, Nishimura M, Saito Y and Iwama A. Clonal expansion of non-leukemic cells expressing two novel MLL-ELL variants differing in transforming activity. Leukemia 22, 861-864, 2008.
  • 樫尾牧子、岩間厚志(2008)「造血幹細胞の増殖制御メカニズム」最新医学 63:2296-2301.
  • 岩間厚志(2008)「白血病幹細胞の自己複製制御機構」医学のあゆみ 227:51-56.
  • 岩間厚志(2008)「造血幹細胞のエピジェネティクスとその制御法の創出」再生医療 7:23-26.
  • 岩間厚志(2008)「白血病幹細胞の自己複製制御機構」臨床血液 49(7):445-54.
  • 岩間厚志 (2008) 「造血幹細胞」「みんなに役立つ造血幹細胞移植の基礎と臨床」(神田善伸編) pp.24-30,医薬ジャーナル,大阪 (2008 )
  • 袁進、岩間厚志 (2008) 「造血幹細胞および白血病幹細胞における自己複製制御機構」血液腫瘍科 56:676-683.
  • 千葉哲博、岩間厚志 (2008)「癌幹細胞におけるエピジェネティクス制御」実験医学 26:1205-1212
  • 岩間厚志 (2008) 「幹細胞研究の現状と今後の展望」新医療 35:113-116

2007年

  • Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Ohkohchi N, Miyoshi H, Nakano M, Nakauchi H, Iwama A, and Taniguchi H. Excessive self-renewal of hepatic stem/progenitor cells drives cancer initiation. Gastroenterology 133, 937-950, 2007.
  • Oguro H and Iwama A. Life and death in hematopoietic stem cells. Curr Opin Immunol 19, 503-509, 2007.
  • Oyama T, Harigaya K, Muradil A, Hozumi K, Habu S, Oguro H, Iwama A, Matsuno K, Sakamoto R, Sato M, Yoshida N, and Kitagawa M. Mastermind-1 is required for Notch signal-dependent steps in lymphocyte development in vivo. Proc Natl Acad Sci USA 104, 9764-9769, 2007.
  • Yamazaki S, Iwama A, Morita Y, Eto K, Ema H, Nakauchi H. Cytokine signaling, lipid raft clustering and HSC hibernation. Ann N Y Acad Sci 1106, 54-63, 2007.
  • Nakazawa Y, Suzuki M, Manabe N, Yamada T, Kihara-Negishi F, Sakurai T, Tenen DG, Iwama A, Mochizuki M, and Oikawa T. Cooperative interaction between Ets1 and Gfi1 transcriptional factors in repression of bax gene expression. Oncogene 26, 3541-3550, 2007.
  • Kato Y, Koseki H, Vidal M, Nakauchi H, and Iwama A. Unique composition of polycomb repressive complex 1 in hematopoietic stem cells. Int J Hematol 85, 179-181, 2007.
  • Negishi M, Saraya A, Miyagi S, Nagao K, Inagaki Y, Nishikawa M, Tajima S, Koseki H, Tsuda H, Takasaki Y, Nakauchi H, and Iwama A. Bmi1 cooperates with Dnmt1 associated protein 1 in gene silencing. Biochem Biophys Res Comm 353, 992-998, 2007.
  • 小黒秀行、岩間厚志(2007)「ポリコーム群蛋白複合体による細胞老化制御」再生医療 6:350-356
  • 千葉哲博、岩間厚志 (2007) 「癌幹細胞」腫瘍内科 1:495-503
  • 岩森巨樹、岩間厚志 (2007) 「精子幹細胞の自己複製に関する転写制御機構」蛋白核酸酵素増刊号Vol25 No16「生殖細胞の発生・エピジェネティクスと再プログラム化」(小倉淳郎,佐々木裕之,仲野徹,松居靖久、中辻憲夫編) pp.2087-2091,共立出版株式会社,東京.
  • 宮城聡、岩間厚志 (2007) 「ポリコーム複合体によるクロマチン構造制御と細胞機能」実験医学増刊号Vol25 No10「転写因子による生命現象解明の最前線」(五十嵐和彦,深水昭吉,大熊芳明,山本雅之編) pp.90-96,羊土社,東京.
  • 武内正博、岩間厚志 (2007) 「白血病幹細胞とその生成機構」血液腫瘍科 54:683-688

2006年

  • Oguro H, Iwama A, Morita Y, Kamijo T, van Lohuizen M, and Nakauchi H. Differential impact of Ink4a and Arf on hematopoietic stem cells and their bone marrow microenvironment in Bmi1-deficient mice. J Exp Med 203, 2247-2253, 2006.
  • Sakaguchi T, Nishimoto M, Miyagi S, Iwama A, Morita Y, Iwamori N, Nakauchi H, Kiyonari H, Muramatsu M, and Okuda A. Putative "stemness" gene Jam-B is not required for maintenance of stem cell state in embryonic, neural, or hematopoietic stem cells. Mol. Cell. Biol. 26, 6557-6570, 2006.
  • Yamazaki S, Iwama A, Takayanagi S-I, Etoh K, Ema H, and Nakauchi H. Cytokine signals modulated via lipid rafts mimics niche signals and induce hibernation in hematopoietic stem cells. EMBO J. 25, 3515-3523, 2006.
  • Chiba T, Kita K, Zheng Y-W, Yokosuka O, Saisho H, Iwama A, Nakauchi H, and Taniguchi T. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44, 240-251, 2006.
  • Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T, and Kitabayashi I. MOZ is essential for maintenance of hematopoietic stem cells. Genes & Dev, 20, 1321-1330, 2006.
  • Arai M, Yokosuka O, Hirasawa Y, Fukai K, Chiba T, Imazeki F, Kanda T, Yatomi M, Takiguchi Y, Seki N, Saisho H, and Ochiai T. Sequential gene expression changes in cancer cell lines after treatment with the demethylation agent 5-Aza-2'-deoxycytidine. Cancer 106, 2514-2525, 2006.
  • Miyagi S, NishimotoM, Saito T, Ninomiya M, Sawamoto K, Okano H, MuramatsuM, Oguro H, Iwama A, and Okuda A. The Sox2 regulatory region 2 functions as a neural stem cell specific enhancer in the telencephalon. J Biol. Chem. 281, 13374-13381, 2006.
  • Takayanagi S, Hiroyama T, Yamazaki S, Nakajima T, Morita Y, Usui J, Eto K, Motohashi T, Shiomi K, Keino-Masu M, Masu M, Oike Y, Mori S, Yoshida N, Iwama A, and Nakauchi H. Genetic marking of hematopoietic stem and endothelial cells: Identification of the Tmtsp gene encoding a novel cell-surface protein with the thrombospondin-1 domain. Blood 107, 4317-4325, 2006.
  • 岩間厚志(2006)「Bmi1」分子細胞医療 5:283-285
  • 加藤裕子、岩間厚志(2006)「白血病幹細胞の起源と自己複製機構」再生医療5:216-221
  • 小黒秀行、中内啓光、岩間厚志 (2006) 「ポリコーム遺伝子Bmi-1による造血幹細胞の自己複製制御」臨床血液 47:363-370
  • 小黒秀行、岩間厚志(2006)「造血幹細胞の自己複製の分子基盤」臨床免疫 45:719-724
  • 小黒秀行、中内啓光、岩間厚志 (2006) 「造血幹細胞の自己複製におけるポリコーム遺伝子Bmi-1の機能」血液フロンティア 16:608-612
  • 菅原武明、岩間厚志(2006)「ポリコーム遺伝子Bmi1による幹細胞制御と白血病発症への関与」血液・腫瘍科 52:598-604
  • 加藤裕子、岩間厚志 (2006)「造血幹細胞の自己増殖におけるSTAT5の意義」血液・腫瘍科 52:167-173
  • 宮城聡、奥田晶彦、岩間厚志 (2006) 「Sox2遺伝子と幹細胞の自己複製制御根」千葉医学雑誌 82:1-7
  • 根岸正充、小黒秀行、加藤裕子、岩間厚志(2006)「ポリコーム遺伝子と幹細胞制御」細胞工学 25:23-27

2005年

  • Matsubara A, Iwama A, Yamazaki S, Furuta C, Hirasawa R, Morita Y, Osawa M, Motohashi T, Eto K, Ema H, Kitamura T, Vestweber D, and Nakauchi H. Endomucin, a CD34-like sialomucin, marks hematopoietic stem cells throughout development. J. Exp. Med. 202, 1483-1492, 2005.
  • Peterson LF, Boyapati A, Ranganathan V, Iwama A, Tenen DG, Schickwan T, and Zhang D-E. The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol. Cell. Biol. 25, 10205-10219, 2005.
  • TCarninci P, Kasukawa T, Katayama S, Gough J, Frith MC, Maeda N, Oyama R, Ravasi T, Lenhard B, Wells C, Kodzius R, Shimokawa K, Bajic VB, Brenner SE, Batalov S, Forrest AR, Zavolan M, Davis MJ, Wilming LG, Aidinis V, Allen JE, Ambesi-Impiombato A, Apweiler R, Aturaliya RN, Bailey TL, Bansal M, Baxter L, Beisel KW, Bersano T, Bono H, Chalk AM, Chiu KP, Choudhary V, Christoffels A, Clutterbuck DR, Crowe ML, Dalla E, Dalrymple BP, de Bono B, Della Gatta G, di Bernardo D, Down T, Engstrom P, Fagiolini M, Faulkner G, Fletcher CF, Fukushima T, Furuno M, Futaki S, Gariboldi M, Georgii-Hemming P, Gingeras TR, Gojobori T, Green RE, Gustincich S, Harbers M, Hayashi Y, Hensch TK, Hirokawa N, Hill D, Huminiecki L, Iacono M, Ikeo K, Iwama A, Ishikawa T, Jakt M, Kanapin A, Katoh M, Kawasawa Y, Kelso J, Kitamura H, Kitano H, Kollias G, Krishnan SP, Kruger A, Kummerfeld SK, Kurochkin IV, Lareau LF, Lazarevic D, Lipovich L, Liu J, Liuni S, McWilliam S, Madan Babu M, Madera M, Marchionni L, Matsuda H, Matsuzawa S, Miki H, Mignone F, Miyake S, Morris K, Mottagui-Tabar S, Mulder N, Nakano N, Nakauchi H, Ng P, Nilsson R, Nishiguchi S, Nishikawa S, Nori F, Ohara O, Okazaki Y, Orlando V, Pang KC, Pavan WJ, Pavesi G, Pesole G, Petrovsky N, Piazza S, Reed J, Reid JF, Ring BZ, Ringwald M, Rost B, Ruan Y, Salzberg SL, Sandelin A, Schneider C, Schönbach C, Sekiguchi K, Semple CA, Seno S, Sessa L, Sheng Y, Shibata Y, Shimada H, Shimada K, Silva D, Sinclair B, Sperling S, Stupka E, Sugiura K, Sultana R, Takenaka Y, Taki K, Tammoja K, Tan SL, Tang S, Taylor MS, Tegner J, Teichmann SA, Ueda HR, van Nimwegen E, Verardo R, Wei CL, Yagi K, Yamanishi H, Zabarovsky E, Zhu S, Zimmer A, Hide W, Bult C, Grimmond SM, Teasdale RD, Liu ET, Brusic V, Quackenbush J, Wahlestedt C, Mattick JS, Hume DA, Kai C, Sasaki D, Tomaru Y, Fukuda S, Kanamori-Katayama M, Suzuki M, Aoki J, Arakawa T, Iida J, Imamura K, Itoh M, Kato T, Kawaji H, Kawagashira N, Kawashima T, Kojima M, Kondo S, Konno H, Nakano K, Ninomiya N, Nishio T, Okada M, Plessy C, Shibata K, Shiraki T, Suzuki S, Tagami M, Waki K, Watahiki A, Okamura-Oho Y, Suzuki H, Kawai J, Hayashizaki Y; FANTOM Consortium; RIKEN Genome Exploration Research Group and Genome Science Group (Genome Network Project Core Group). The FANTOM Consortium. The transcriptional landscape of the mammalian genome. Science 309, 1559-1563, 2005.
  • Nakauchi H, Oguro H, Negishi M, Iwama A. Polycomb gene product Bmi-1 regulates stem cell self-renewal. Ernst Schering Res Found Workshop. 54, 85-100, 2005.
  • Kato Y, Iwama A, Tadokoro Y, Shimoda K, Akira S, Tanaka M, Miyajima A, Kitamura T, and Nakauchi H. Selective activation of STAT5 unveils its role in stem cell self-renewal in normal and leukemic hematopoiesis. J. Exp. Med. 202, 169-179, 2005.
  • Choi YL, Moriuchi R, Osawa M, Iwama A, Makishima H, Wada T, Kisanuki H, Kaneda R, Ota J, Koinuma K, Ishikawa M, Takada S, Yamashita Y, Oshimi K, and Mano H. Retroviral expression screening of oncogenes in natural killer cell leukemia. Leuk. Res. 29, 943-949, 2005.
  • Chiba T., Yokosuka O, Fukai K, Hirasawa Y, Tada M, Mikata R, Imazeki F, Taniguchi H, Iwama A, Miyazaki M, Ochiai T, and Saisho H. Identification and investigation of methylated genes in Hepatoma. Eur. J. Cancer 41, 1185-1194, 2005.
  • Iseki H, Shimizukawa R, Sugiyama F, Kunita S, Iwama A, Onodera M, Nakauchi H, and Yagami KI. Parvovirus NS induces an epigenetic modification through histone acetylation in host genes and reverts tumor malignancy to benignancy. J. Virol. 79, 8886-8893, 2005.
  • Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama S, Perkins A, Mucenski ML, Suda T, and Morishita K. Oncogenic transcription factor Evi-1 regulates hematopoietic stem cell expansion through the GATA-2 expression. EMBO J, 24, 1976-1987, 2005.
  • Iwama A, Oguro H, Negishi M, Kato Y, and Nakauchi H. Epigenetic regulation of hematopoietic stem cell self-renewal by polycomb group genes (Review). Int. J. Hematol. 81, 294-300, 2005.
  • Numata A, Shimoda K, Kamezaki K, Haro T, Kakumitsu H, Shide K, Kato K, Miyamoto T, Yamashita Y, Oshima Y, Nakajima H, Iwama A, Aoki K, Takase K, Gondo H, Mano H, and Harada M. Signal transducers and activators of transcription 3 augments the transcriptional activity of CCAAT/enhancer binding protein α in G-CSF signaling pathway. J Biol Chem 280,12621-12629, 2005.
  • 加藤裕子、岩間厚志(2005)「白血病幹細胞の概念とその分子機構」Medical Science Digest 31:340-344
  • 岩間厚志、小黒秀行、加藤裕子、中内啓光(2005)「ポリコーム遺伝子Bmi-1と幹細胞制御」Molecular Medicine臨時増刊号「免疫2006」42:133-139
  • 岩間厚志(2005) 「ポリコーム遺伝子Bmi-1による造血幹細胞制御」医学のあゆみ別冊「血液疾患 ver.3」55-58
  • 武内正博、岩間厚志 (2005) 「C/EBP転写因子群と白血病」血液腫瘍科 51:563-569
  • 岩間厚志 (2005) 「siRNAを用いた標的遺伝子ノックダウンによる白血病治療の可能性」血液腫瘍科 51:16-20
  • 岩間厚志(2005)「幹細胞の自己複製メカニズム」最新医学60:1740-1746
  • 岩間厚志、中内啓光(2005)「造血幹細胞の自己複製制御機構」炎症と免疫13:72-79

2004年

  • Iwama A, Oguro H, Negishi M, Kato Y, Morita Y, Tsukui H, Ema H, Kamijo T, Katoh-Fukui Y, Koseki H, van Lohuizen M, and Nakauchi H. Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product, Bmi-1. Immunity 21, 843-851, 2004.
  • Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M, Honda K, Shinohara H, Sudo K, Tsuji K, Nakauchi H, Iwakura Y, Hirai H, Oda H, Yamamoto T and Yamanashi Y. Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J. Exp. Med. 200, 1681-1687, 2004.
  • Miyagi S, Saito T, Mizutani K-I, Masuyama N, Gotoh Y, Iwama A, Nakauchi H, Masui S, Niwa H, Nishimoto M, Muramatsu M, and Okuda A. The Sox-2 regulatory regions display their activities in two distinct multipotent stem cells. Mol. Cell. Biol. 15, 4207-4220, 2004.
  • Rosenbauer F, Wagner K, Zhang P, Knobeloch K-P, Iwama A, and Tenen DG. pDP4, a novel glycoprotein secreted by mature granulocytes is regulated by transcription factor PU.1. Blood 103, 4294-4301, 2004.
  • 岩間厚志、中内啓光(2004)「ポリコーム群タンパク質による造血幹細胞制御」実験医学22:350-355
  • 岩間厚志、中内啓光(2004)「ポリコーム群遺伝子による幹細胞制御」Medical Science Digest 30:308-309
  • 岩間厚志(2004)「顆粒球分化と白血病発症におけるC/EBPファミリー」血液腫瘍科 49:35-41
  • 岩間厚志(2004)「Fc融合蛋白の作成」実験医学別冊「バイオ研究に必ず役立つ免疫学的実験法」(中内啓光編) pp.120-126,羊土社,東京 (2004).

2003年

  • Suzuki A, Iwama A, Miyashita H, Nakauchi H, Taniguchi H. Role for growth factors and extracellular matrix in controlling differentiation of prospectively isolated hepatic stem cells. Development 130, 2513-2524, 2003.
  • Yotsumoto K, Okoshi Y, Shibuya K, Yamazaki S, Tahara-Hanaoka S, Honda S, Osawa M, Kuroiwa A, Matsuda Y, Tenen DG, Iwama A, Nakauchi H, and Shibuya A. Paired activating and inhibitory immunoglobulin-like receptors, MAIR-I and ?II, regulate mast cell and macrophage myeloid activation, J. Exp. Med. 198, 223-233, 2003.
  • Noguchi E, Iwama A, Takeda K, Takeda T, Kamioka M, Ichikawa K, Akiba T, Arinami T, and Shibasaki M. The promoter polymorphism in the eosinophil cationic protein gene and its influence on the serum eosinophil cationic protein level. Am. J. Respir. Crit. Care. Med. 167,180-184, 2003.

2002年

  • Osawa M, Yamaguchi T, Nakamura Y, Kaneko S, Onodera M, Sawada K-I, Nakauchi H*, and Iwama A* (*corresponding author). Erythroid expansion mediated by Gfi-1B zinc finger protein: its implication in normal hematopoiesis. Blood 100, 2769-2777, 2002.
  • Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK, Tenen DG, Hiddemann W, and Behre G. The granulocytic inducer C/EBP? inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood 100, 483-490, 2002.
  • Iwama A*, Osawa M, Hirasawa R, Uchiyama N, Kaneko S, Onodera M, Shibuya K, Shibuya A, Vinson C, Tenen DG, and Nakauchi H* (*corresponding author). Reciprocal roles for C/EBP and PU.1 transcription factors in Langerhans cell commitment. J. Exp. Med. 195, 547-558, 2002.
  • Hirasawa R, Shimizu R, Takahashi S, Osawa M, Takayanagi S, Kato Y, Onodera M, Minegishi N, Yamamoto M, Fukao K, Taniguchi H, Nakauchi H*, and Iwama A* (*corresponding author). Essential and instructive roles of GATA factors in eosinophil development. J. Exp. Med. 195, 1379-1386, 2002.
  • Morotomi-Yano K, Yano K-I, Saito H, Sun Z, Iwama A, and Miki Y. Human RFX4 is a testis-specific transcription factor that interacts physically with other human RFX members. J. Biol. Chem. 277, 836-842, 2002.
  • Sone H, Shimano H, Sakakura Y, Inoue N, Amemiya-Kudo M, Yahagi N, Osawa M, Suzuki H, Yokoo T, Takahashi A, Iida K, Toyoshima H, Iwama A, Yamada N.Acetyl-coenzyme A synthetase is a lipogenic enzyme controlled by SREBP-1 and energy status. Am. J. Physiol. Endocrinol. Metab. 282, E222-230, 2002.